A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros (Q85300346)
Jump to navigation
Jump to search
scientific article published on 26 October 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant pros |
scientific article published on 26 October 2012 |
Statements
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer (English)
A Heidenreich
S K Rawal
K Szkarlat
N Bogdanova
L Dirix
A Stenzl
M Welslau
G Wang
F Dawkins
C J de Boer
26 October 2012